Opposed Behavioural Outputs of Increased Dopamine Transmission in Prefrontocortical and Subcortical Areas: A Role for

P. Vezina1, G. Blanc, J. Glowinski

  • 1Chaire de Neuropharmacologie, INSERM U. 114, Collège de France, 11, place Marcelin Berthelot, 75231 Paris Cedex 05, France.

Insights

Dopamine in the medial prefrontal cortex (mPFC) inhibits locomotion. Blocking D-1 dopamine receptors in the mPFC enhances amphetamine-induced locomotion, providing direct evidence for dopamine's inhibitory role in motor behavior.

Area of Science:

  • Neuroscience
  • Behavioral Neuroscience
  • Psychopharmacology

Background:

  • Previous studies suggested dopamine in the medial prefrontal cortex (mPFC) inhibits locomotor behavior, but evidence was indirect.
  • Prior research primarily used permanent dopamine depletion, limiting the understanding of acute dopamine function.

Purpose of the Study:

  • To provide direct evidence for the inhibitory role of medial prefrontal cortex (mPFC) dopamine on locomotor activity.
  • To investigate the specific dopamine receptor subtype involved in this inhibitory pathway.

Main Methods:

  • Rats received local injections of amphetamine into the mPFC to acutely increase dopamine transmission.
  • Locomotor activity was assessed following mPFC amphetamine administration.
  • The effects of intra-mPFC injections of the D-1 dopamine receptor antagonist SCH-23390 on locomotion were examined, alongside other dopamine receptor antagonists.

Main Results:

  • Acute increases in dopamine transmission in the mPFC by amphetamine injections inhibited the locomotor-activating effects of amphetamine in the nucleus accumbens (N.Acc.).
  • Intra-mPFC administration of SCH-23390, a D-1 dopamine receptor antagonist, enhanced locomotion induced by intra-N.Acc. amphetamine.
  • Other dopamine antagonists with different receptor affinities did not produce this enhancement, indicating D-1 receptor specificity.

Conclusions:

  • These findings provide direct evidence that dopamine acting in the mPFC inhibits locomotor activity.
  • The results strongly suggest that this inhibitory effect is mediated via D-1 dopamine receptors within the mPFC.

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.